AR and prostate carcinoma: Resveratrol (3,4′,5-trans-trihydroxystilbene), a precursor to pinostilbene (3,4′-dihydroxy-5-methoxystilbene), has been shown to have anticancer activity against prostate cancer and to inhibit transcription activity of AR as well as its protein expression51.